Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15218531 | 0.89 | CNR2 (0.39) | POLBFFAR4NPY5RIDO1NR3C1 | |
| SCHEMBL15218540 | 0.88 | ALDH1A1 (0.46) | POLBALDH1A1NPY5RIDO1NR3C1 | |
| SCHEMBL15218527 | 0.84 | ALDH1A1 (0.46) | POLBALDH1A1IDO1KDM4ELMNA | |
| SCHEMBL15209523 | 0.83 | POLB (0.48) | POLBALDH1A1FFAR4NPY5RNR3C1 | |
| SCHEMBL22667955 | 0.82 | PHGDH (0.33) | NPY5RNR3C1LMNA | |
| SCHEMBL17663511 | 0.78 | ALDH1A1 (0.39) | POLBALDH1A1NPY5RIDO1NR3C1 | |
| SCHEMBL17737455 | 0.78 | IDO1 (0.55) | ALDH1A1FFAR4IDO1LMNAMEN1 | |
| SCHEMBL15218533 | 0.76 | IDO1 (0.39) | POLBNPY5RIDO1SCN9A | |
| SCHEMBL22375467 | 0.76 | ALDH1A1 (0.50) | POLBALDH1A1LMNACYP17A1HSD11B1 | |
| SCHEMBL16558119 | 0.76 | TRPV1 (0.41) | ALDH1A1NPY5RNR3C1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322410-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CHEMOCENTRYX INC (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2021202731-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | CHEMOCENTRYX, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210308119-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | CHEMOCENTRYX, INC. | 2021-10-07 | — | — | US | disclosed |
| US-11045469-B2 | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies | CHEMOCENTRYX, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11020394-B2 | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies | CHEMOCENTRYX, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200268751-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CHEMOCENTRYX INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CHEMOCENTRYX INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200113898-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CHEMOCENTRYX, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-2820006-B1 | PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR9 ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016057424-A1 | COMBINATION THERAPY OF INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CHEMOCENTRYX, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160095921-A1 | Combinations and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies | CHEMOCENTRYX, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20150073017-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8916601-B2 | Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916601-B2 | Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2013130811-A1 | PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR9 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225580-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225580-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045469-B2 | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies | CCR9, CCR4, ITGB7 | POLB 1423/4885ALDH1A1 2337/4885FFAR4 320/4885 |
| US-20210308119-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES | CCR9, CCR3, CCR1 | POLB 2346/4885ALDH1A1 3025/4885FFAR4 1361/4885 |
| US-20130225580-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | POLB 3503/4885ALDH1A1 1144/4885FFAR4 483/4885 |
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR9, CCR1, CCR3 | POLB 3503/4885ALDH1A1 1144/4885FFAR4 483/4885 |
| US-20200113898-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CCR9, ITGB7, CCR4 | POLB 1181/4885ALDH1A1 2410/4885FFAR4 329/4885 |
| US-20150073017-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | POLB 3503/4885ALDH1A1 1144/4885FFAR4 483/4885 |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CCR9, CCR1, CCR3 | POLB 3719/4885ALDH1A1 1216/4885FFAR4 449/4885 |
| US-20160095921-A1 | Combinations and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies | CCR9, CCR4, ITGB7 | POLB 1173/4885ALDH1A1 2024/4885FFAR4 300/4885 |
| US-11020394-B2 | Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies | CCR9, CCR4, ITGB7 | POLB 1427/4885ALDH1A1 2292/4885FFAR4 322/4885 |
| US-20210322410-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CCR9, ITGB7, CCR4 | POLB 1181/4885ALDH1A1 2410/4885FFAR4 329/4885 |
| US-20200268751-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES | CCR9, ITGB7, CCR4 | POLB 1181/4885ALDH1A1 2410/4885FFAR4 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.